In the post-pandemic years, SARS-CoV-2 morbidity and mortality declined due to less pathogenic variants, active and passive immunization, and antiviral therapies. However, patients with hematological malignancies and/or undergoing hematopoietic cell transplantation (HCT) remain at increased risk for poor outcomes. Therefore, adherence to contact and droplet precautions is essential to avoid transmission

We read the article “A novel lncRNA SNHG29 regulates EP300-related histone acetylation modification and inhibits FLT3-ITD AML development” by Liu Shan et al. with great interest [1]. The study identified the role of the novel lncRNA SNHG29 in FLT3-ITD acute myeloid leukemia (AML), demonstrating that it suppresses AML progression by binding to and regulating the histone acetyltransferase EP300, thereby

Drug development is deemed successful for patients not only on the basis of regulatory approval, but when the optimal, and ideally the minimal effective dose and schedule is determined [1]. This allows us to offer patients new approved treatments safely, and with the most optimized balance of risk and benefit. In clinical practice, many drugs in oncology are often given to patients at a dose and schedule

T-cell Acute Lymphoblastic Leukaemia (T-ALL) is a high-risk hematological disease constituting ~20% of acute leukemias. To date, the only subtype recognized by the World Health Organization’s International Consensus Classification is early T-cell precursor ALL. To improve clinical outcomes, several studies have investigated and defined T-ALL genomic subtypes within cohorts of varied ages and geographical

Prognostic scores are an important tool in medical statistics. In chronic myeloid leukaemia (CML), prognostic models have existed for many years, enabling the classification of patients into groups that can be clearly differentiated in terms of their prognosis. However, over time, the focus of these models has shifted from solely survival outcomes to a broader range of diverse endpoints. This review